Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Wilms tumor of the kidney characterized by the predominance of the blastema component.
Biomarker and diagnostic research for blastema predominant kidney Wilms tumor has been reported in the published literature.
No clinical trials have been registered for blastema predominant kidney Wilms tumor.
4 publications have been identified in PubMed for blastema predominant kidney Wilms tumor. Research spans Review / Meta-Analysis (50%), Diagnostic / Biomarker (25%), and Basic Science / Preclinical (25%).
Götz L (2025). [PMID: 39740515](https://pubmed.ncbi.nlm.nih.gov/39740515/). *Transl Oncol*. [Diagnostic / Biomarker]
Perlman EJ (2025). [PMID: 40231423](https://pubmed.ncbi.nlm.nih.gov/40231423/). *Histopathology*. [Review / Meta-Analysis]
Salzillo C (2025). [PMID: 39918792](https://pubmed.ncbi.nlm.nih.gov/39918792/). *Curr Oncol Rep*. [Review / Meta-Analysis]
Ma G (2024). [PMID: 39368485](https://pubmed.ncbi.nlm.nih.gov/39368485/). *Cell Rep Med*. [Basic Science / Preclinical]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.